Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edward M Messing

Showing results (131-140 of 199) with videos related to

Pageof 20
Sort By:
BJU International|May 27, 2015
Bladder cancer incidence and mortality in patients treated with radiation for uterine cancerJanet E Baack Kukreja, Emil Scosyrev, Ralph A Brasacchio, et al.
Cancer Cell International|August 14, 2003
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell lineJay E Reeder, Mark P Sowden, Edward M Messing, et al.
Cancer Research|November 5, 2002
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cellsYi-Fen Lee, Wen-Jye Lin, Jiaoti Huang, et al.
The Lancet. Oncology|June 6, 2006
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomyEdward M Messing, Judith Manola, Jorge Yao, et al.
BMC Urology|April 8, 2004
Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulatorHani H Rashid, Jay E Reeder, Mary J O'Connell, et al.
Urologic Oncology|July 22, 2008
Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology GroupJeffrey M Ignatoff, Yu-Hui Chen, Richard Evan Greenberg, et al.
Carcinogenesis|December 31, 2013
Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3Spencer Slavin, Chiuan-Ren Yeh, Jun Da, et al.
The Journal of Urology|September 8, 2005
Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United StatesEdward M Messing, Lisa Teot, Howard Korman, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2011
Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimensJennifer Gordetsky, Emelian Scosyrev, Hani Rashid, et al.
Anticancer Research|February 7, 2016
Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer PatientsDeepak Kilari, Kenneth A Iczkowski, Chintan Pandya, et al.
Pageof 20

Showing results (131-140 of 199) with videos related to

Sort By:
Pageof 20
BJU International|May 27, 2015
Bladder cancer incidence and mortality in patients treated with radiation for uterine cancerJanet E Baack Kukreja, Emil Scosyrev, Ralph A Brasacchio, et al.
Cancer Cell International|August 14, 2003
Inducible expression of catalytically active type 1 serine/threonine protein phosphatase in a human carcinoma cell lineJay E Reeder, Mark P Sowden, Edward M Messing, et al.
Cancer Research|November 5, 2002
Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cellsYi-Fen Lee, Wen-Jye Lin, Jiaoti Huang, et al.
The Lancet. Oncology|June 6, 2006
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomyEdward M Messing, Judith Manola, Jorge Yao, et al.
BMC Urology|April 8, 2004
Interstitial cystitis antiproliferative factor (APF) as a cell-cycle modulatorHani H Rashid, Jay E Reeder, Mary J O'Connell, et al.
Urologic Oncology|July 22, 2008
Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): a trial of the Eastern Cooperative Oncology GroupJeffrey M Ignatoff, Yu-Hui Chen, Richard Evan Greenberg, et al.
Carcinogenesis|December 31, 2013
Estrogen receptor α in cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3Spencer Slavin, Chiuan-Ren Yeh, Jun Da, et al.
The Journal of Urology|September 8, 2005
Performance of urine test in patients monitored for recurrence of bladder cancer: a multicenter study in the United StatesEdward M Messing, Lisa Teot, Howard Korman, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 13, 2011
Identifying additional lymph nodes in radical cystectomy lymphadenectomy specimensJennifer Gordetsky, Emelian Scosyrev, Hani Rashid, et al.
Anticancer Research|February 7, 2016
Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer PatientsDeepak Kilari, Kenneth A Iczkowski, Chintan Pandya, et al.
Pageof 20